Epilepsy

Neurology News Network for the week ending August 21, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 20, 2021.

Patients with focal seizures showed a median 25.2% reduction in the frequency of focal seizures, the most common seizure type in patients with tuberous sclerosis complex.

Recent advances in stereoelectroencephalography and laser ablation may help convert those who may be candidates for pediatric epilepsy surgery to those who proceed with a consultation.

The chief medical officer of NeuroPace discussed the newly developed nSight Platform, which allows physicians to remotely track seizure burden and activity for patients with drug-resistant focal epilepsy.

Successful epilepsy surgery in adults has been followed by forced normalization, depression, and memory issues, resulting in questions about the use of the metrics in the study of broader outcomes—a problem even more prominent in pediatric epilepsy surgery.

Program chairs Fred D. Lublin, MD, and Stephen Silberstein, MD, offer insight into the third annual IFN meeting, which is set for September 17-18, 2021, to be held in a virtual setting.

Here's what is coming soon to NeurologyLive.

Investigators compared 4 treatment groups, concluding that nonstandard therapies were less effective in enacting freedom from treatment failure.

Neurology News Network for the week ending August 14, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 13, 2021.

Surgery for eligible patients was shown to increase rates of seizure freedom, as well as improve developmental levels, among those with TSC.

A lateralization effect was observed for patients with left temporal lobe epilepsy, as their BrainAGE values more closely resembled control group values following surgery.

Here's what is coming soon to NeurologyLive.

Jianbin Tang, data scientist and research leader from IBM Research Australia, and colleagues spoke on findings from their recent study and plans for a newly developed artificial intelligence-based model.

Neurology News Network for the week ending August 7, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 6, 2021.

There was no evidence of increased risk of suicidal ideation or attempt overall or for any individual antiseizure medication in a meta-analysis of 5 newer ASMs.

Led by a team of top talents, NYU Langone’s Comprehensive Epilepsy Center’s contributions to drug development and improving the quality of life for patients stand among the field's most important.

Preliminary results showed that a fusion of accelerometry and blood volume post modalities achieved the best AUC-ROC for 9 combined seizure types.

Aquestive does not anticipate a need for any additional studies and is preparing for the commercial launch of Libervant in the first half of 2022, if approved.

Here's what is coming soon to NeurologyLive.

Joseph Sullivan, MD, and Elaine C. Wirrell, discuss the transition of care into adulthood of patients with Dravet syndrome.

Key opinion leaders discuss managing patient expectations regarding clinical trials for Dravet syndrome treatment.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 30, 2021.